Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Akcea Therapeutics Inc (NASDAQ:AKCA) and Atara Biotherapeutics (NASDAQ:ATRA).
Akcea Therapeutics Inc (AKCA)
Cowen & Co. analyst Ritu Baral maintained a Hold rating on Akcea Therapeutics Inc yesterday. The company’s shares opened today at $25.48.
According to TipRanks.com, Baral is a top 100 analyst with an average return of 31.0% and a 54.0% success rate. Baral covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals Inc, Allena Pharmaceuticals Inc, and Ionis Pharmaceuticals Inc.
Akcea Therapeutics Inc has an analyst consensus of Moderate Buy, with a price target consensus of $32.50, representing a 27.6% upside. In a report issued on August 28, Stifel Nicolaus also maintained a Hold rating on the stock with a $25 price target.
.
See today’s analyst top recommended stocks >>
Atara Biotherapeutics (ATRA)
In a report released yesterday, Phil Nadeau from Cowen & Co. reiterated a Buy rating on Atara Biotherapeutics. The company’s shares opened today at $38.35.
According to TipRanks.com, Nadeau is a 5-star analyst with an average return of 12.5% and a 56.2% success rate. Nadeau covers the Healthcare sector, focusing on stocks such as Rhythm Pharmaceuticals Inc, Rocket Pharmaceuticals Inc, and Alexion Pharmaceuticals.
Currently, the analyst consensus on Atara Biotherapeutics is a Strong Buy with an average price target of $57.50.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
